Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) PT at $27.14

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been assigned an average rating of “Moderate Buy” from the ten ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $27.1429.

A number of brokerages recently weighed in on ZVRA. BTIG Research decreased their price objective on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Monday, July 27th. Maxim Group lifted their target price on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Citizens Jmp boosted their target price on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, August 6th. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Canaccord Genuity Group decreased their price target on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, July 27th.

Insider Activity at Zevra Therapeutics

In related news, Director Corey Michael Watton sold 12,300 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the completion of the transaction, the director owned 1,800 shares in the company, valued at $20,250. The trade was a 87.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 3.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP increased its position in shares of Zevra Therapeutics by 5.2% during the second quarter. Wellington Management Group LLP now owns 164,538 shares of the company’s stock worth $2,359,000 after purchasing an additional 8,121 shares in the last quarter. Globeflex Capital L P acquired a new stake in shares of Zevra Therapeutics in the 2nd quarter worth $2,752,000. Bank of New York Mellon Corp purchased a new position in Zevra Therapeutics during the 2nd quarter worth $2,846,000. Hennion & Walsh Asset Management Inc. grew its stake in Zevra Therapeutics by 116.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after buying an additional 206,543 shares during the last quarter. Finally, Quantinno Capital Management LP grew its stake in Zevra Therapeutics by 114.1% during the 1st quarter. Quantinno Capital Management LP now owns 32,022 shares of the company’s stock worth $298,000 after buying an additional 17,065 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Stock Down 0.2%

Shares of NASDAQ:ZVRA opened at $11.87 on Wednesday. The company has a market capitalization of $704.84 million, a price-to-earnings ratio of 12.90 and a beta of 0.91. Zevra Therapeutics has a 52 week low of $7.16 and a 52 week high of $15.03. The firm has a 50 day moving average of $12.23 and a 200 day moving average of $10.76.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.14. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%.The business had revenue of $39.66 million for the quarter, compared to analysts’ expectations of $33.88 million. On average, sell-side analysts expect that Zevra Therapeutics will post 0.6 EPS for the current year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.